20:38 , Mar 12, 2019 |  BC Extra  |  Company News

UC strengthens CRISPR IP position with new patent

The USPTO issued a third patent covering fundamental aspects of the CRISPR-Cas9 technology to The Regents of the University of California, the University of Vienna and Emmanuelle Charpentier, strengthening the group's patent position in the...
22:33 , Feb 8, 2019 |  BC Extra  |  Company News

USPTO to grant UC foundational CRISPR patent

A notice of allowance on a core CRISPR patent application will put IP covering the most foundational aspects of the game-changing gene editing technology in the hands of two rival parties. The Regents of the...
17:56 , Jan 22, 2019 |  BC Extra  |  Company News

Bosley leaving Editas as CRISPR company moves toward clinic

Editas Medicine Inc. (NASDAQ:EDIT) said Katrine Bosley is stepping down as president and CEO, effective March 1. Cynthia Collins, a director since December, will be interim CEO while the gene editing company searches for a...
03:40 , Jan 18, 2019 |  BC Innovations  |  Product R&D

Modality moves at Vertex

In licensing a suite of newly discovered gene editing tools, Vertex Pharmaceuticals Inc. is broadening its options for solving problems that its core small molecule technology can’t address. On Jan. 3, Vertex announced a deal...
00:29 , Dec 22, 2018 |  BC Extra  |  Financial News

Markets deliver biotech lump of coal

Biotech indexes fell about 4% on Friday, with CRISPR stocks taking a particularly hard hit, and ended the week down double digits as the broader market fell on macroeconomic concerns. Continued tension over a trade...
22:09 , Dec 17, 2018 |  BC Extra  |  Company News

Management tracks: Vertex’s Graney joins Generation Bio

Tom Graney has left Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) as CFO to take on the same role at non-viral gene therapy company Generation Bio Co. (Cambridge, Mass.). Ian Smith, Vertex EVP and COO and former CFO,...
03:31 , Dec 7, 2018 |  BC Innovations  |  Tools & Techniques

Germline editing gets technical

As the smoke clears from Jiankui He’s bombshell germline editing announcement, the gap between where the gene editing field is now and where it would need to be to support responsible germline editing has become...
19:59 , Nov 2, 2018 |  BC Week In Review  |  Company News

UC Regents issued second CRISPR patent in U.S.

The Regents of the University of California, the University of Vienna and Emmanuelle Charpentier were granted a patent by the U.S. Patent Office covering use of guide RNA formats in CRISPR-Cas9 gene editing technology. The...
22:38 , Nov 1, 2018 |  BC Extra  |  Company News

Management tracks: CuraSen names Vargas CMO; plus Sosei, Casebia

Neurodegenerative disease start-up CuraSen Therapeutics Inc. (San Mateo, Calif.) hired Gabriel Vargas as its first CMO. Vargas led early development of migraine prophylactic Aimovig erenumab at Amgen Inc. (NASDAQ:AMGN), where he was most recently executive...
22:55 , Oct 30, 2018 |  BC Extra  |  Company News

Management tracks: Blueprint, Clovis

Ahead of the anticipated 2019 launch of avapritinib, Blueprint Medicines Corp. (NASDAQ:BPMC) hired Christina Rossi into the newly created role of chief commercial officer. She was the multiple sclerosis business unit head of North America...